In 5 random groups of Wistar rats (n= 15 for each group), ulcerogenic doses of NSAIDs COX-
1-COX-2 inhibitors such as indomethacin were compared with Celecoxib (COX-2 inhibitor); …

Five experimental models were developed in different groups of Wistar rats (N= 15) to study
selective COX-2-inhibitor NSAIDs such as celecoxib and rofecoxib, as follows:(1) dose …

Selective COX-2 inhibitors have been shown to produce fewer gastrointestinal adverse
reactionsthan classical NSAIDs. Nevertheless, these new agents may worsen and delay the …

Conclusion Dose-dependent administration of celecoxib and rofecoxib as COX-2 inhibitors
and non-COX-1 inhibitors, respectively, did not produce toxic injuries on healthy …

Selective COX-2 inhibitor, celecoxib, delays the healing of gastric ulcers by inhibiting
prostaglandins synthesis. Therefore, the effect of celecoxib on normal and acid-challenged …

Celecoxib is a frequently used nonsteroidal anti-inflammatory drug (NSAID) in the treatment
of rheumatoid arthritis and osteoarthritis. It selectively inhibits cyclooxygenase II (COX-2) …

Background. Recent studies have revealed that cyclooxygenase-2 is involved in the
protection of the damaged gastric mucosa, mediating, in particular, the acceleration of ulcer …

The pharmacological profile of celecoxib (CAS 169590-42-5, SC-58635), a specific
cyclooxygenase-2 (COX-2) inhibitor, was investigated. Celecoxib inhibited COX-2-mediated …

OBJECTIVE: To compare the gastric mucosal damage induced by a COX‐2 inhibitor,
celecoxib, and a conventional NSAID, indomethacin. METHODS: A rat model of NSAID …

Background: It is suggested that the gastrointestinal toxicity of conventional non-steroid anti-
inflammatory drugs (NSAIDs) is due to a'topical'effect in addition to inhibition of the mucosal …